IC
SAGE

Ikarian Capital’s Sage Therapeutics SAGE Stock Holding History

Ikarian Capital’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-250,000
Closed -$14.2M – 251
2021
Q2 		$14.2M Hold
250,000
– – 1.15% 20
2021
Q1 		$18.7M Buy
+250,000
New +$20.5M 0.63% 34

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ikarian Capital's SAGE Position: Q2 2023 in Review

Ikarian Capital sold out of Sage Therapeutics (SAGE) in Q2 2023, closing a stake of 17,805 shares — an estimated $747K sold.

Ikarian Capital first reported a position in SAGE in Q4 2019 and held it in 10 quarters. The position peaked at $9.6M in Q4 2019. 224 funds tracked by Wall St. Rank hold SAGE as of Q2 2023.

  • Ikarian Capital reported no remaining Sage Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Ikarian Capital sold 17,805 Sage Therapeutics shares in Q2 2023, an estimated $747K.
  • Ikarian Capital first reported a position in Sage Therapeutics in Q4 2019 and held it in 10 quarters.
  • Ikarian Capital's Sage Therapeutics position peaked at $9.6M in Q4 2019.
  • 224 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2023.

Based on Ikarian Capital's 13F filing for Q2 2023, filed 14 Aug 2023.